Your browser doesn't support javascript.
loading
Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy.
Buckey, Timothy M; Sun, Di; Spergel, Jonathan M.
Affiliation
  • Buckey TM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: timothy.buckey@pennmedicine.upenn.edu.
  • Sun D; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Spergel JM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ann Allergy Asthma Immunol ; 133(1): 18-19, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38960561
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anti-Allergic Agents / Omalizumab / Food Hypersensitivity Limits: Humans Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anti-Allergic Agents / Omalizumab / Food Hypersensitivity Limits: Humans Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article